7HN-46216-19760
2 vaccinations
1 coded response
11 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 835 / ID
- Registered
- 2021-01-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-20
Dose 1 — Moderna
-
2021-01-30
Registered in v-safe
- 2021-01-30
- 2021-02-03
- 2021-02-10
-
2021-02-17
Dose 2 — Moderna
-
2021-02-24
Health check-in — day 7, dose 2Feeling: Good · None · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
- 2021-03-03
- 2021-03-10
- 2021-03-19
- 2021-03-24
- 2021-03-31
-
2021-08-18
Survey response — 6 months, dose 2MedDRA: Uterine dilation and curettage, Uterine leiomyoma — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: Fibroids · Healthcare visit (other): Surgery-myosure dncMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-08-18
Report sent to call center — 6 months, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-08-25
- 2022-02-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-20 | Moderna | |
| 2 | 2021-02-17 | Moderna |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-08-18 | Unsuccessful |
Free text
Release 9 — 6 months, dose 2
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Uterine dilation and curettage | ✓ | · | ✓ |
| SD | Uterine leiomyoma | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release